Showing 1211-1220 of 1325 results for "".
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- Coherent Ships 5,000th OEM ExciStar Devicehttps://modernod.com/news/coherent-ships-5000th-oem-excistar-device/2478427/Coherent recently delivered the 5,000th OEM ExciStar laser for refractive corneal surgery. “The longevity of the laser components and the excellent pulse stability at the ultra-short 193 nm laser wavelength have made the ExciStar family the ideal ablation source for ever faster and m
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- WHO Suspends Hydroxychloroquine Arm in Global COVID-19 Trial Amid Safety Reviewhttps://modernod.com/news/who-suspends-hydroxychloroquine-arm-in-global-covid-19-trial-amid-safety-review/2477821/The World Health Organization (WHO) has implemented a temporary pause of the hydroxychloroquine arm within the agency’s Solidarity Trial in COVID-19 patients pending a review of safety data by the study’s Data Safety M
- Aldeyra Therapeutics Announces Potential of ADX-629 to Treat COVID-19 Patientshttps://modernod.com/news/aldeyra-therapeutics-announces-potential-of-adx-629-to-treat-covid-19-patients/2477578/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, plans to facilitate the clinical testing of its drug candidate ADX-629 in patients with COVID-19-associated respiratory compromise. The company has requested a pre-investigational new drug m
- Novavax Accelerates Initiation of COVID-19 Vaccine Trial to Mid-Mayhttps://modernod.com/news/novavax-accelerates-initiation-of-covid-19-vaccine-trial-to-mid-may/2477554/Novavax announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M adjuvant will be incorporated w
- Mayo Clinic’s Jonathan Holmes, MD, Appointed UArizona Chair of Ophthalmologyhttps://modernod.com/news/mayo-clinics-jonathan-holmes-md-appointed-uarizona-chair-of-ophthalmology/2477537/Jonathan M. Holmes, MD, has been appointed chair of the University of Arizona College of Medicine – Tucson Department of Ophthalmology, effective Friday, July 31. Dr. Holmes currently serves as the Joseph E. and Rose Marie Green Professor of Visual Sciences and professor of ophthalmology a
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m